MANKIND PHARMA
Back to Income Statement
|
MANKIND PHARMA Last 5 Year Consolidated Net Profit History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Consolidated Net Profit | ₹1,282 Cr | ₹1,433 Cr | ₹1,265 Cr | ₹1,030 Cr | ₹579 Cr |
What is the latest Consolidated Net Profit of MANKIND PHARMA ?
Year | Consolidated Net Profit |
---|---|
Mar2023 | ₹1,282 Cr |
Mar2022 | ₹1,433 Cr |
Mar2021 | ₹1,265 Cr |
Mar2020 | ₹1,030 Cr |
Mar2019 | ₹579 Cr |
How is Consolidated Net Profit of MANKIND PHARMA Trending?
Years | Consolidated Net Profit | % Change | |
---|---|---|---|
Mar2023 | ₹1,282 Cr | -10.58 | |
Mar2022 | ₹1,433 Cr | 13.28 | |
Mar2021 | ₹1,265 Cr | 22.81 | |
Mar2020 | ₹1,030 Cr | 78.11 | |
Mar2019 | ₹579 Cr | - |
Compare Consolidated Net Profit of peers of MANKIND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MANKIND PHARMA | ₹83,875.6 Cr | 0.1% | -11.8% | 59.3% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹350,195.0 Cr | -1.1% | -2.9% | 55.1% | Stock Analytics | |
CIPLA | ₹118,275.0 Cr | 0.3% | 6.1% | 56.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹117,130.0 Cr | 8.2% | 11.5% | 27.9% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹102,998.0 Cr | -3.7% | 8.5% | 107.7% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹98,034.1 Cr | 1.8% | -4.7% | 32.3% | Stock Analytics |
MANKIND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MANKIND PHARMA | 0.1% |
-11.8% |
59.3% |
SENSEX | -2% |
-1.1% |
19.4% |
You may also like the below Video Courses